TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Beam Therapeutics
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics presented promising clinical trial results for risto-cel, a base editing cell therapy for sickle cell disease, showing high hemoglobin F induction, reduced hemoglobin S, and durable anemia resolution in 31 patients.

Insights
BEAM   positive

Reported strong clinical trial results with high editing efficiency, rapid patient engraftment, and no severe vaso-occlusive crises, indicating promising progress in developing a potential transformative therapy for sickle cell disease